Roche hands over another batch of positive PhIII data on its new flu drug, looking for an early-winter launch
Roche has taken another big stride toward gaining approval for its new flu therapy — eyeing a market launch just as winter is set to get …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
